Healthcare's 'Silos of Silence' Are The Biggest Barrier To Clinical AI At Scale

Healthcare generates mountains of data, yet the systems holding it fundamentally fail to communicate with one another. Instead of waiting for a universal standard that may never arrive, the industry is turning to AI orchestration layers to act as real-time translators, bridging the legacy platforms, inconsistent taxonomies, and fragmented records that leave roughly half of healthcare's data stale or inaccessible.

Shammy Narayanan is the Senior Vice President of Data, AI, and Platform Architecture at the healthcare tech provider Welldoc. He has spent 25 years moving artificial intelligence from concept to production across the healthcare and BFSI sectors. Today, he leads executive AI experimentation and clinical operations, focusing on how clinical AI can serve as a translation layer for systems of record that don't speak the same language. On a recent episode of the Beyond the IT Headlines podcast, Welcome to the Agentic Era: Healthcare's Next AI Transformation, Narayanan outlined what that translation layer looks like in practice and where the technology is heading next.

More inputs, more confusion

The scale of the disconnect starts with something as basic as a blood pressure reading. A single patient might register a reading on a home app, take another at a pharmacy kiosk, and have a third recorded in an electronic health record, all within a span of two hours. "Which is the right source of truth? We don't know," Narayanan said. Blood pressure alone can be represented in four different ways within a single healthcare system, and much of the data underpinning clinical decisions still hasn't made the leap to digital. "Some of this data we're talking about is still on paper, which has to be converted into a digital format through OCR," he explained.

Even where digitization has occurred, legacy platforms carry significant technical debt, and the explosion of consumer IoT devices has compounded the problem. As wearables, pharmacy kiosks, and clinical instruments all generate readings for the same biomarker, each source creates its own version of the truth. Without a strategy for aligning fragmented data sources, more inputs often mean more confusion. "The systems don't speak the same language. You need an orchestration layer to convert and map the data so it all aligns," Narayanan said. "Today we're in silos of silence where you have data that is either too vast, fragmented, or unavailable. And even if it is available, it doesn't talk to each other effectively."

From ambient scribes to agentic workflows

Breaking through that fragmentation requires more than better integration. Narayanan outlined a three-stage progression that moves clinical AI from a documentation tool to an autonomous care coordinator. The first stage—ambient scribes—is already in production. These systems listen to patient-physician conversations and generate clinical notes in real time, freeing up face time for actual care. "The system is not new. But its accuracy has gone up, its efficiency has gone up, and that will continue to happen as the models progress."

The second stage is multimodal reasoning. Rather than analyzing a single data source in isolation, multimodal AI synthesizes inputs from across the patient's ecosystem, including imaging, wearable data, activity patterns, and genomic profiles. "Am I just reading your X-ray? No, I have access to your Fitbit, so I can understand your activity pattern," Narayanan explained. "Can I combine all this information and make a very accurate judgment far better than what we used to do in the past?" This kind of cross-system synthesis is already reshaping how organizations think about data pipelines, though healthcare's regulatory and interoperability requirements make the implementation uniquely complex.

The third stage, and the one Narayanan sees arriving before the end of 2026, is agentic AI. In this model, AI agents don't just analyze data. They act on it. An agent reads a patient's treatment plan, schedules physician visits, communicates with pharmacies about prescriptions, and handles medication adherence follow-ups. "Earlier we used to do all this as a point solution," Narayanan said. "Now I'm going to look at it in a comprehensive way."

The regulatory green light

Moving these capabilities from pilot into production requires regulatory backing, and the FDA has been adjusting its guidance to keep pace. Narayanan pointed to several 2026 regulatory changes that signal a meaningful shift in how the agency views clinical AI, with the most significant involving diagnostic confidence. Previously, even when an AI algorithm was highly certain about a patient's condition, it was required to present multiple possible diagnoses. That requirement has been relaxed. If the system can explain its reasoning, it can deliver a single conclusion. "If you are very clear, just say 'this is what it is,' as long as you're able to explain it," Narayanan said. "The algorithm should be able to explain how it arrived at this conclusion."

The changes extend to emergency care and consumer devices. In critical situations like emergency triage, AI systems can now bypass traditional human review requirements, provided the algorithm is classified as a high-risk medical device and can document its reasoning. "There is a critical condition where you don't have time. You can depend on the AI as long as that explainable AI is there," he explained. Meanwhile, consumer wearables like the Apple Watch and Oura Ring can now cover a broader range of health factors, including glucose trends and blood pressure, as long as they stop short of definitive diagnostic claims. "It can give you trends, it can give you insights. Still, a physician has to confirm it. But they have expanded that ambit." Taken together, the regulatory direction suggests that the era of treating clinical AI purely as a risk factor is giving way to a framework that views it as a capable copilot for clinical decision-making.

Care without the calendar

The convergence of better data infrastructure, multimodal reasoning, and regulatory flexibility opens the door to a fundamentally different model of chronic care. Narayanan describes a near-future scenario in which AI copilots manage the daily routines of patients with conditions like heart failure and diabetes, and some components are already technically possible. Using AI-enabled smart glasses, for instance, a patient could look at a restaurant menu and receive real-time guidance calibrated to their caloric intake and medication schedule. "That recommendation will come to you in real time as you look at the menu," said Narayanan. The broader industry is already moving toward ambient, personalized health guidance, suggesting the vision isn't as far off as it sounds.

But the most consequential shift may be in how patients interact with the healthcare system itself. Today, physician visits are scheduled on fixed intervals. 'Come back in a month.' 'Come back in a quarter.' Narayanan envisions a model where that cadence becomes event-driven rather than time-driven. An agent from the patient's side continuously shares data with an agent at the physician's office. If everything looks good, the visit gets deferred automatically. If something looks off, the system flags it. "You're not even involved here," he noted. "There's an exchange of information, data-driven decisions are made, and you're free to do what you're doing unless the AI decides otherwise."

Further out, the same data infrastructure could enable digital twin simulations for individual patients, allowing organizations to simulate treatments against a digital replica of the patient's unique biomarkers rather than relying on real-world trial and error. "With the digital twin, we will be able to make more accurate predictions." The same approach could compress drug discovery timelines for rare diseases, where small patient populations have historically made R&D economics prohibitive. "It will create an equalizing field where even rare diseases can be addressed with the same efficiency as common diseases today," he said.

The infrastructure challenges between here and autonomous care copilots are real, but the building blocks are coming together faster than most observers expected. For Narayanan, the trajectory points toward a healthcare system that finally treats its data as a connected asset rather than a collection of isolated readings. "Prescriptive medicine, personalized medicine, is not too far away. Given that each one of us is unique and our biomarkers are unique, why shouldn't the medicine be unique?" he concluded.